Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PORTIA-28 vs ADQUEY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive: estrogen (ethinyl estradiol) suppresses gonadotropin release, inhibiting ovulation; progestin (levonorgestrel) alters cervical mucus and endometrial lining.
ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.
Prevention of pregnancy
Alzheimer disease (FDA approved for treatment of mild cognitive impairment or mild dementia stage),Off-label: none established
One tablet (levonorgestrel 0.15 mg, ethinyl estradiol 0.03 mg) orally once daily
400 mg orally once daily with food.
Levonorgestrel: 24-30 hours; ethinyl estradiol: 12-15 hours. Clinical context: Steady-state achieved within 5-7 days.
Terminal half-life 12-15 hours; prolonged in renal impairment (up to 30 hours in Cr Cl <30 m L/min)
Hepatic: ethinyl estradiol and levonorgestrel are metabolized via CYP3A4, conjugation, and sulfation.
Metabolized via catabolic pathways similar to endogenous Ig G; no specific cytochrome P450 enzyme involvement.
Renal (60-70% as metabolites, 20-30% as levonorgestrel/ethinyl estradiol glucuronides), fecal (10-20%), biliary (minor).
Renal: 70-80% unchanged; Fecal: 5-10% as metabolites; Biliary: minimal (<2%)
Levonorgestrel: 97.5-99% to sex hormone-binding globulin (SHBG) and albumin; ethinyl estradiol: 98-99% to albumin.
98% bound to albumin
Levonorgestrel: 1.8 L/kg (extensive tissue distribution).
0.2-0.3 L/kg; indicates limited extravascular distribution
Oral: levonorgestrel ~100%, ethinyl estradiol ~40-45% (first-pass metabolism).
Oral: 85-90%; IM: 95-100%
No dose adjustment required for mild to moderate renal impairment; contraindicated in severe renal disease
Cr Cl ≥60 m L/min: no adjustment; Cr Cl 30-59 m L/min: 200 mg daily; Cr Cl <30 m L/min: 100 mg daily; hemodialysis: 100 mg daily after dialysis.
Contraindicated in acute hepatic disease or severe cirrhosis (Child-Pugh C); use with caution in mild to moderate hepatic impairment
Child-Pugh A: no adjustment; Child-Pugh B: 200 mg daily; Child-Pugh C: not recommended.
Use only after menarche; dose as per adult schedule (one tablet daily)
Weight ≥10 kg: 12 mg/kg/dose twice daily; weight <10 kg: 8 mg/kg/dose twice daily.
Not indicated for postmenopausal women
Initial dose 200 mg daily; titrate based on renal function; monitor for neuropsychiatric effects.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Amyloid-related imaging abnormalities (ARIA), including ARIA-E (edema/effusion) and ARIA-H (hemosiderin deposition), can occur. ARIA is usually asymptomatic but serious events including seizure and status epilepticus have been reported. Patients with apolipoprotein E ε4 homozygosity have a higher incidence of ARIA.
Increased risk of thromboembolic disorders (VTE, MI, stroke),Hepatic neoplasia,Hypertension,Gallbladder disease,Carbohydrate/lipid metabolism effects,Bleeding irregularities
1) Amyloid-related imaging abnormalities (ARIA): monitor with MRI before and during treatment; consider dose interruption or discontinuation if severe. 2) Hypersensitivity reactions: angioedema, urticaria reported. 3) Risk of falls due to cognitive impairment. 4) No head-to-head trials showing superiority over other treatments.
Thrombophlebitis or thromboembolic disorders,Cerebrovascular or coronary artery disease,Known or suspected pregnancy,Undiagnosed abnormal genital bleeding,Known or suspected breast cancer,Liver tumors or active liver disease,Hypersensitivity to any component,Use with Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir with or without dasabuvir
History of severe hypersensitivity to aducanumab or any excipients in ADQUEY.
Grapefruit and grapefruit juice may increase ethinyl estradiol levels and risk of adverse effects; avoid concurrent consumption. No other significant food interactions. Maintain consistent dietary habits as changes in diet may affect drug absorption. Do not consume alcohol excessively as it may increase risk of liver toxicity and reduce contraceptive efficacy.
Avoid grapefruit and grapefruit juice; may increase drug levels. High-fat meals can increase absorption; take with food or on an empty stomach consistently.
Pregnancy category X. Contraindicated in pregnancy. First trimester exposure associated with cardiovascular defects, neural tube defects, and limb reduction anomalies. Second and third trimester exposure may cause fetal adrenal suppression, virilization of female fetuses due to progestin component, and potential long-term neurodevelopmental effects. Postnatal effects include possible behavioral issues.
ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Second and third trimester exposure may lead to feminization of male fetuses and other adverse outcomes.
Excreted into breast milk. M/P ratio not well established; progestins and estrogens are present in low levels. Potential for adverse effects on infant such as jaundice and breast enlargement. Generally not recommended during breastfeeding; alternative contraception advised.
Excretion into breast milk is minimal; however, ADQUEY may reduce milk production and quality. M/P ratio not established. Avoid use during breastfeeding.
Not applicable; contraindicated in pregnancy. No dose adjustment recommendations exist as use is contraindicated.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue immediately if pregnancy occurs.
Portia-28 is a combination oral contraceptive (COC) containing ethinyl estradiol and levonorgestrel. Initiate on the first day of menstrual bleeding or the first Sunday after onset; if starting after day 5, use backup contraception for 7 days. Missed pill management: if one pill is missed, take it as soon as remembered and continue regular schedule (may take two pills in one day); if two or more pills are missed, take the most recent missed pill, discard others, use backup contraception for 7 days, and consider emergency contraception if unprotected intercourse occurred. Maximum efficacy requires daily adherence at the same time. CYP3A4 inducers (e.g., rifampin, St. John's wort) may reduce contraceptive effectiveness; consider alternative non-hormonal methods during co-administration. Portia-28 may increase serum potassium; caution with potassium-sparing diuretics, ACE inhibitors, or ARBs. Discontinue if migraines with aura, unexplained visual loss, or signs of thromboembolism occur. Monitor blood pressure and liver function periodically.
Administration with a full glass of water and staying upright for 30 minutes reduces risk of esophagitis. Monitor for cutaneous lupus erythematosus and Stevens-Johnson syndrome. Avoid concomitant use with drugs that prolong QT interval due to risk of torsades de pointes.
Take one tablet daily at the same time each day, with or without food. Do not skip doses.,If you miss a pill, refer to the missed pill instructions in the package insert; use backup contraception if needed.,Portia-28 does not protect against HIV or other sexually transmitted infections; use condoms for STI prevention.,Smoking increases risk of serious cardiovascular events; avoid smoking, especially if over age 35.,Contact your healthcare provider immediately if you experience chest pain, shortness of breath, leg swelling, severe headache, vision changes, or jaundice.,Inform your doctor of all medications you take, including over-the-counter drugs and herbal supplements.,Store at room temperature away from moisture and heat; keep out of reach of children.
Take exactly as prescribed; do not double doses if missed.,Swallow tablet whole; do not crush or chew.,Avoid direct sunlight; use sunscreen and protective clothing.,Report any skin rash, blisters, or eye irritation immediately.,Do not take with antacids, iron supplements, or sucralfate; separate by at least 4 hours.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PORTIA-28 vs ADQUEY, answered by our medical review team.
PORTIA-28 is a Oral Contraceptive that works by Combination oral contraceptive: estrogen (ethinyl estradiol) suppresses gonadotropin release, inhibiting ovulation; progestin (levonorgestrel) alters cervical mucus and endometrial lining.. ADQUEY is a Oral Contraceptive that works by ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PORTIA-28 and ADQUEY depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PORTIA-28 is: One tablet (levonorgestrel 0.15 mg, ethinyl estradiol 0.03 mg) orally once daily. The standard adult dose of ADQUEY is: 400 mg orally once daily with food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PORTIA-28 and ADQUEY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PORTIA-28 is classified as Category C. Pregnancy category X. Contraindicated in pregnancy. First trimester exposure associated with cardiovascular defects, neural tube defects, and limb reduction anomalies. Second and t. ADQUEY is classified as Category C. ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Sec. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.